ArticleInternational forum of allergy & rhinology2023
A comparative analysis of endoscopic sinus surgery versus biologics for treatment of chronic rhinosinusitis with nasal polyposis.
Article in International forum of allergy & rhinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 4 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Biologics and Surgery in Chronic Rhinosinusitis With Nasal Polyps: A Comparative Outcomes Analysis.American journal of rhinology & allergy · 2025Pooled it
- Effect of Dupilumab in CRSwNP Sinonasal Outcomes from Real Life Studies: A Systematic Review with Meta-analysis.Current allergy and asthma reports · 2025Pooled it
- Bibliometric analysis of biologic treatments for chronic rhinosinusitis.Frontiers in medicine · 2025Pooled it
- Endoscopic Extended Sinus Surgery for Patients with Severe Chronic Rhinosinusitis with Nasal Polyps, the Choice of Mucoplasty: A Systematic Review.Current allergy and asthma reports · 2023Pooled it
- Superior Benefits of Combining Mepolizumab With Sinus Surgery Compared to Mepolizumab Alone: Results From a Randomised 6-Month Trial.International forum of allergy & rhinology · 2025Trial
- Comparison of Dupilumab and Revision Endoscopic Sinus Surgery for Recurrent Chronic Rhinosinusitis with Nasal Polyps: A Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Importance of Smell Loss to Patients With Chronic Rhinosinusitis With Nasal Polyps: Options for Management and Recovery.Clinical and translational allergy · 2026Review
- Biologics in Chronic Rhinosinusitis with Nasal Polyps: The Otolaryngologist's Perspective.Current allergy and asthma reports · 2026Review
- Advance in biologics for chronic rhinosinusitis with nasal polyps.Frontiers in allergy · 2026Review
- Prognostic value of preoperative prognostic nutritional index and its association with systemic inflammatory response markers in chronic rhinosinusitis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025Article
- Biologics for Chronic Rhinosinusitis With Nasal Polyposis: Current Landscape and Future Directions.Laryngoscope investigative otolaryngology · 2025Review
- A Literature Review of the Management of Nasal Polyps: Biologics Combined With Endoscopic Surgery.Cureus · 2025Review
- The Efficacy of Dupilumab as an Adjuvant Treatment After Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyps: A Retrospective Cohort Analysis.Clinical and experimental otorhinolaryngology · 2025Article
- Mechanisms, diagnosis, and treatment of olfactory dysfunction in rhinosinusitis.European journal of medical research · 2025Review
- Clinical efficacy and mechanisms of biologics for chronic rhinosinusitis with nasal polyps.The Journal of allergy and clinical immunology · 2025Review
- Sirt5 affects the metabolic remodeling of eosinophils by negatively regulating the level of succinylation modification of Pkm2 in eosinophilic chronic rhinosinusitis.World journal of otorhinolaryngology - head and neck surgery · 2025Article
- Dupilumab in the Treatment of Severe Uncontrolled Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and Comorbid Asthma-A Multidisciplinary Monocentric Real-Life Study.Biomedicines · 2025Article
- Effects of endoscopic minimally invasive surgery on olfactory function and quality of life in patients with chronic rhinosinusitis and nasal polyps.American journal of translational research · 2025Article
- Comparative efficacy of combined steroid and omalizumab therapy following the surgical treatment of chronic polypous rhinosinusitis in adults.Postepy dermatologii i alergologii · 2025Article
- How does asthma coexistence affect the strategic selection of biologic therapies in CRSwNP management?Frontiers in allergy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundComparative effectiveness research between endoscopic sinus surgery (ESS) and biologic therapy for severe chronic rhinosinusitis with nasal polyposis (CRSwNP) is a nascent field as new therapeutic modalities become clinically available.
methodsA prospective, multicenter cohort of CRSwNP patients, undergoing ESS between 2011 and 2019, were compared to phase-3 biologic trial data. Patients undergoing ESS received baseline nasal endoscopy quantified via Lund-Kennedy (LK) grading. Patients meeting inclusion criteria, modified from Dupilumab-LIBERTY-NP-24&52, omalizumab-POLYP-1&2, and Mepolizumab-SYNAPSE clinical trials, were included in this study. Baseline characteristics and outcome measures were compared between these cohorts at 24 weeks and 52 weeks, when possible.
resultsA total of 111 CRSwNP patients met modified inclusion criteria. There were no statistically significant differences in baseline age, sex, asthma status, aspirin-exacerbated respiratory disease status, smell identification, LK-polyp score, and Lund-Mackay computed tomography (CT) scores between ESS and biologic groups. At 24 weeks, ESS demonstrated significantly greater improvements in 22-item Sino-Nasal Outcome Test (SNOT-22) compared to one (of two) dupilumab trials (p < 0.05) and both omalizumab trials (p < 0.001). ESS associated with significantly lower nasal polyp scores (NPS) compared to dupilumab (p < 0.001) and omalizumab (p < 0.001), despite comparable improvements in smell identification (p > 0.05). At 52 weeks, ESS resulted in statistically similar improvement in SNOT-22 scores compared to dupilumab (p = 0.21), but NPS remained significantly lower in the ESS group compared to dupilumab (p < 0.001) and mepolizumab (p < 0.001).
conclusionAt 24 weeks and 52 weeks, ESS offers comparable SNOT-22 improvements compared to dupilumab. ESS and dupilumab offer comparable improvement in smell identification at 24 weeks. Compared to omalizumab, ESS offers superior SNOT-22 improvements. ESS offers significantly greater reductions in polyp size compared to omalizumab, dupilumab, and mepolizumab therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.